Clinical success of anti-infective combination therapy compare to monotherapy in patients with carbapenem-resistant Pseudomonas aeruginosa infection: a 10-years retrospective study

Background Carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection has become a major public health concern. The recommendations for monotherapy and combination therapy in the current guidelines lack sufficient evidence to support them. The primary objective of this study is to determine the ef...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:BMC infectious diseases Ročník 24; číslo 1; s. 248 - 10
Hlavní autori: Chen, Jialong, Lin, Jing, Weng, Jianzhen, Ju, Yang, Li, Yanming
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London BioMed Central 23.02.2024
BioMed Central Ltd
Springer Nature B.V
BMC
Predmet:
Adult
Anti-Bacterial Agents - therapeutic use
Antibiotics
Antiinfectives and antibacterials
Antimicrobial agents
Blood pressure
Carbapenem-resistant Pseudomonas aeruginosa
Carbapenems
Carbapenems - therapeutic use
Combination therapy
Comorbidity
Comparative analysis
Critical care
Disease
Drug therapy
Drug therapy, Combination
Effectiveness
Ethnicity
Humans
Infectious Diseases
Intensive care
Internal Medicine
Length of stay
Medical Microbiology
Medical prognosis
Medicine
Medicine & Public Health
Monotherapy
Mortality
Nosocomial infections
Parasitology
Patients
Pharmacology, Experimental
Pneumonia
Pseudomonas aeruginosa
Pseudomonas aeruginosa infections
Pseudomonas Infections - drug therapy
Public health
Regression analysis
Retrospective Studies
Risk factors
Sepsis
Structured Query Language-SQL
Success
Survival analysis
Therapy
Tropical Medicine
Ventilators
China
Carbapenem-resistant
Effectiveness
Combination therapy
Monotherapy
Carbapenem-resistant Pseudomonas aeruginosa
ISSN:1471-2334, 1471-2334
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Background Carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection has become a major public health concern. The recommendations for monotherapy and combination therapy in the current guidelines lack sufficient evidence to support them. The primary objective of this study is to determine the effectiveness of anti-Infective combination therapy compared to monotherapy in achieving clinical success in patients with CRPA infection and risk factors of clinical failure of monotherapy. Methods A retrospective study from Medical Information Mart for Intensive Care IV (MIMIC-IV) was conducted. We included adults with infections caused by CRPA. The outcomes of this study were clinical success, complete clinical success, and 28-day all-cause mortality. Results A total of 279 subjects were finally enrolled. The rate of clinical success for combination therapy was higher than that for monotherapy (73.1% versus 60.4%, p =0.028). Compared to clinical failure patients, patients in the clinical success group were more likely to die within 28 days after CRPA was found (48.3% versus 3.6%, p <0.001). In a multivariate logistic regression analysis, monotherapy was found to be significantly correlated with clinical success (OR, 0.559, 95% CI, 0.321-0.976; p = 0.041). Conclusion Combination therapy is more effective for CRPA infection patients, especially those whose SOFA score is ≥ 2 or whose Charlson comorbidity index is ≥ 6.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1471-2334
1471-2334
DOI:10.1186/s12879-024-09060-2